ALISO VIEJO, Calif.--(BUSINESS WIRE)--AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today provided an update on the STAR trial and announced that it has completed additional pre-clinical and clinical studies to enhance the complete response to the approvable letter for the new lower dose Zenvia™ (dextromethorphan 30mg/quinidine 10mg [DM/Q 30/10]) formulation. The Company has also announced that the NASDAQ exchange has extended the temporary suspension of bid price requirements, which is expected to permit the continued listing of the Company’s Common Stock on the NASDAQ Global Market until at least November 13, 2009.
